Syngene International Ltd. · NSE:SYNGENE
Syngene International — Q4 FY23 Earnings Presentation
38 slides from Syngene International's earnings presentation, Apr 26, 2023
Slide 1: Cover letter to stock exchanges
Ref: Syn/CS/SE/IP/2023-24/Apr/12 Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560099, Karnataka, India. T +91 80 6891 8000 F +91 80 6891 8808 CIN: L85110KA1993PLC014937 www.syngeneintl.com April 26, 2023 To,
Slide 2: Investor Presentation April 2023
Investor Presentation April 2023
Slide 3: Safe harbour
Safe harbour Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements
Slide 4: Contents
Contents 1 Operating Highlights 2 Syngene – Putting Science to Work 3 Syngene strengths 4 Financials 5 Shareholding and Share Information Appendix Putting Science to Work 3
Slide 5: Operating Highlights
Ml Operating Highlights Syngene
Slide 6: Q4 FY23 performance
Q4 FY23 performance Operating Highlights Q4 Financial Highlights • Strong growth in the fourth quarter, added to a positive performance over the course of the year • The growth of Discovery Services and Dedicated Centers remained steady. The research facility in Hyderabad, which is a vital part of o
Slide 7: Full Year FY23 performance
Full Year FY23 performance Operating Highlights FY23 Financial Highlights • Delivered full-year results ahead of our upgraded guidance • FY23 delivered the highest absolute year-on-year increase in revenue and EBITDA in the last 5 years Total Revenue Reported EBITDA • All four divisions of the Compa
Slide 8: Syngene – Putting Science to Work
2 Syngene – Putting Science to Work
Slide 9: Partner in innovation: #Puttingsciencetowork
Partner in innovation: #Puttingsciencetowork Who we are and what we do We aim to be a world class partner delivering innovative scientific solutions for clients We offer integrated Sector expertise include Our team includes more Established track record in solutions across pharmaceuticals, biotech,
Slide 10: Key facts and figures
Key facts and figures 400+ 15 400+ World class active clients collaborations patents infrastructure with top 20 pharmaceutical held with clients of 2 Mn+ sq. ft. qualified to companies meet international standards Rs. 45,587 Mn Rs. 32,638 Mn Rs. 4,644 Mn ~6,000+ headcount (US$563Mn*) (US$403Mn*) (US
Slide 11: International accreditations
International accreditations • USFDA,OHSAS 18001 • GLP, cGMP, AAALAC & CPCSEA Certified facilities • CAP accreditation, ISO/IEC 27001:2013 accreditation • EMA and PMDA approved, AAALAC accredited facility • The safety assessment laboratories and large molecule bioanalytical lab are ISO IEC 17025:201
Slide 12: Our experience spans multiple industry segments and partnerships
Our experience spans multiple industry segments and partnerships with global leaders across the world Large & Emerging Animal Consumer mid-sized Universities Agrochem biopharma health products biopharma Putting Science to Work 11
Slide 13: Our journey so far
Our journey so far 2019 – 2023 Continued investments and Globalization and strategic collaboration • Expanded into formulations development growth • Contract with Endo Pharmaceuticals to develop novel anti cancer • Expanded collaboration with BMS, biological therapeutic molecules Amgen and Zoetis •
Slide 14: Our broad capabilities spanning the value chain
Our broad capabilities, spanning the value chain, facilitates integration and captures additional benefits for clients Research business Development and Manufacturing business Discovery Services Dedicated R&D Centers Development Services Manufacturing Services Flexible Platform with capability acros
Slide 15: A 'one-stop-shop' for discovery, development and manufacturing
A 'one-stop-shop' for discovery research, development and manufacturing services (small and large molecules) Discovery Development Manufacturing Small Drug Substance Chemistry Molecules Large Development Clinical Supplies Molecules Drug Product Development Biology Integrated Drug Substance – Drug Pr
Slide 16: Flexible collaboration models
Flexible collaboration models 1 2 3 4 5 6 Dedicated R&D centers Full time equivalent (FTE) Fee for service Productivity-based model Risk-reward Delivery-based contract for CDMO business • Dedicated scientific • Pre-defined numbers • Client contracts for • Resources and services • Relationship spans
Slide 17: Our state-of-the-art infrastructure
Our state-of-the-art infrastructure Bangalore campus 90 acres housing most of Syngene’s capabilities Discovery Services Hyderabad campus commenced operation in Aug 2019 API Manufacturing Mangalore campus Biologics Commissioned March 2020 Bangalore campus Capacity: 70KL Manufacturing plant scale: Rea
Slide 18: Experienced workforce: building capabilities and careers
Experienced workforce: building capabilities and careers ~6,000+ Inspiring technical excellence and providing opportunities to grow total headcount Nurturing young • Syngene Training Academy offers new graduate recruits a six-month extended induction to help them 5000+ scientists talent and enhancin
Slide 19: Operational robustness driving strategy execution
Operational robustness driving strategy execution Continuous improvement embedded in operations Focused execution through strong Project driven by certified operational leaders Management Six Sigma Black Belt certified staff in each service line and Structured program management for executing client
Slide 20: Syngene strengths
3 Syngene strengths Syngene
Slide 21: Syngene strengths
Syngene strengths A global scale CRO/CDMO Solutions through innovation Quality matters • Integrated Drug Discovery, Development and • IP fully assigned to clients • Fully digitized quality organization Manufacturing service provider • Track record of data management and • Strong compliance track rec
Slide 22: Strong track record of growth and profitability
Strong track record of growth and profitability Total Revenue (Rs. Mn) EBITDA (Rs. Mn) Profit Before Tax * (Rs. Mn) FY19 to FY23 - CAGR 14% FY19 to FY23 - CAGR 13% FY19to FY18 toFY22 FY23--CAGR CAGR8% 9% 32,638 10,053 5,936 26,570 5,151 8,489 20,935 22,489 7,364 4,456 4,342 6,995 4,154 19,007 6,119
Slide 23: Levers for future growth
Levers for future growth Expand/extend existing clients Capacity expansion • Service integration • Continuous investment • Flexible business models including • FTE services, manufacturing, formulation, dedicated centers biologics, stability Engage New Clients • Tailored service offerings, high quali
Slide 24: Committed to safety and sustainability
Committed to safety and sustainability Safety is our first priority Committed to environmental protection • Accredited with ISO 45001:2018 for Occupational Health and Safety • Accredited with ISO 14001:2015 for our Environment Management (OH&S) measures System • Risk assessments are an integral part
Slide 25: Industry recognition for our scientific capability and best practices
Industry recognition for our scientific capability and best practices • Bio-Excellence Award 2018: At Bengaluru • CMO Leadership Award Winner 2020 - under • CMO Leadership Awards 2022 Received 6 awards for all Tech Summit, Bengaluru Categories: Capabilities, Compatibility, categories, including Capa
Slide 26: Robust risk management framework
Robust risk management framework Syngene has a risk management framework to identify, monitor, report and manage risk Every risk owner monitors and manages risks relevant to their area of responsibility Executive Committee (EC) Board of Directors(BOD) • Sign-off on Enterprise Risk Framework annually
Slide 27: Financials
4 Financials
Slide 28: Q4FY23 financial highlights
Q4FY23 financial highlights Particulars Q4 FY23 Q4 FY22 YoY change Q3 FY23 QoQ change Revenue from operations 9,944 7,581 31% 7,859 27% Other income 228 147 56% 172 32% Reported revenue 10,172 7,728 32% 8,031 27% Material costs 2,938 2,149 37% 2,061 43% Staff costs 2,528 1,797 41% 2,192 15% Other di
Slide 29: FY23 financial highlights
FY23 financial highlights Particulars FY23 FY22 YoY Change Revenue from operations 31,929 26,042 23% Other income 710 528 34% Reported revenue 32,639 26,570 23% Balance Sheet Highlights Material costs 8,602 7,490 15% Staff costs 8,876 7,408 20% As on 31st March 2023 Other direct costs 1,109 872 27%
Slide 30: Shareholding and Share Information
Shareholding and Share 5 Information
Slide 31: Syngene and Biocon Group
Syngene and Biocon Group Syngene is an operationally independent publicly listed Biocon Limited, founded in 1978, is an innovation-led global subsidiary of Biocon Limited, established in 1993 as India’s biopharmaceuticals company and has majority holding in key first Contract Research Organization.
Slide 32: Shareholding and Share Information
Shareholding and Share Information Syngene’s Shareholding Pattern* Syngene’s Share Information* 1.0% NSE Ticker SYNGENE BSE Ticker 539268 Promoter & Promoter Group Market Cap (Rs. Mn) 2,38,653 44.1% Public 54.9% % free-float 44% ESOP Trust Free-float market cap (Rs. Mn) 1,05,290 Share Outstanding (M
Slide 33: For more details
For more details Visit our website www.syngeneintl.com https://twitter.com/SyngeneIntl https://www.linkedin.com/company/syngene-international-limited https://www.facebook.com/syngeneintl/ https://www.youtube.com/channel/UCIC4WSA1k5YAC531gMLkbIQ IR Contact: Media Contact: Krishnan G/ Suruchi Daga Sho
Slide 34: Appendix
J Appendix Syngene
Slide 35: Discovery Services
Discovery Services Target Identification and Hit HitHit to Lead to Lead Optimization Lead IND Enabling IND IND IND / Ph1 / DE Validation Identification Lead Optimization Enabling Ph1 DE Target ID In vitro assays: In In vitro vitro assays: assays: In Invivo vivoassays/studies: assays/studies: Later T
Slide 36: Development Services and Manufacturing Services
Development Services and Manufacturing Services Developability Development Clinical Phase Registration/process Commercial Assessment phase Phase I Phase II Phase III validation batches Early PK, MTD/DRF studies, • IND enabling GLP Tox studies: Ames, Chromosomal • NDA enabling studies: Sub- chronic a
Slide 37: Biologics Development and Manufacturing services
Biologics Development and Manufacturing services Developability Development Clinical Phase Registration/process Commercial Assessment phase Phase I Phase II Phase III validation batches • Cell line development / • Clone to GMP • Process DOE, robustness and safety study selection • Upstream process O
Slide 38: Thank you
Thank you © 2023 Syngene International Limited, Bengaluru, India. All Rights Reserved. Syngene believes the information in this document is accurate as of its publication date; such information is subject to change without notice. Syngene acknowledges the proprietary rights of other companies to the
Syngene International — Q4 FY23 Earnings Presentation on 6ix